U.S. Uterine Fibroid Treatment Market

U.S. Uterine Fibroid Treatment Market, By Procedure Type (Endometrial Ablation, MRI Guided Procedures (MRI-guided Percutaneous Laser Ablation, and MRI-guided Transcutaneous Focused Ultrasound), Hysterectomy (Abdominal Hysterectomy, Vaginal Hysterectomy, Laparoscopic Hysterectomy, Robotic Hysterectomy, and Hysteroscopic Morcellation), Myomectomy (Open Myomectomy, Laparoscopic Myomectomy, and Robotic Myomectomy), Uterine Artery Embolization, Radiofrequency Ablation, and Others) and By End User (Hospitals and Ambulatory Surgical Centers)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Uterine fibroid is a benign tumor of the woman’s uterus formed of smooth muscle that are found on the wall of the uterus i.e. within the wall of uterine wall or can attach to the uterine wall. Uterine fibroid grow as a single tumor or in clusters and these uterine fibroid can lead to pelvic pain, excessive menstrual bleeding, and frequent urination. Uterine fibroids majorly develop in 50% of women, which have led to increased rate of hysterectomy i.e. removal of the uterus. Uterine fibroid develops in women that often have a family history of fibroids. The uterine fibroid is formed and grown in response to the stimulation by hormone estrogen that is produced naturally in the body. Various types of uterine fibroid treatment are available in the market as the technology advanced, which include minimal invasive surgical treatment that help to control the growth of uterine fibroid. Uterine fibroid can be treated by both surgery and medications, the surgery include the treatment of uterine fibroid by hysterectomy, cryosurgery, myomectomy, uterine artery embolization, and MRI-guided high-intensity focused ultrasound. The market is likely to be driven by the high prevalence of uterine fibroids among women worldwide, increased patient preference for less invasive procedures, and the adoption of technologically sophisticated technologies. Excessive menstrual flow, pelvic pain, infertility, and frequent urination are all symptoms of uterine fibroid (UF), a benign tumor of the smooth muscle cells that grow in the uterus. Even though the etiology is unknown, race, age, genetic susceptibility, premenopausal status, hypertension, overweight, and diet are all risk factors.

Market Dynamics

Rising incidence of uterine fibroids among women and adoption of minimally invasive treatments is expected to propel the growth of U.S. uterine fibroids treatment market over the forecast period. With the rising incidence of uterine fibroids, the key market players are focusing on the various growth strategies such as acquisitions and partnerships. For instance, in August 2020, Hologic, Inc., a medical technology company primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging, announced that it has acquired Acessa Health Inc., a privately-held innovator in minimally invasive treatment for fibroids, for approximately US$ 80 million in cash plus contingent payments based on future revenue growth.

Key features of the study:

• This report provides in-depth analysis of the U.S. uterine fibroids treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. uterine fibroids treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Blue Endo, Boston Scientific Corporation or its affiliates, CooperSurgical, Inc., Karl Storz SE & Co. KG, Myovant Sciences GmbH (Sumitovant Biopharma Ltd.), Halt Medical, Inc. (Hologic, Inc.), LiNA Medical ApS, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• U.S. uterine fibroids treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. uterine fibroids treatment market

Detailed Segmentation:

• U.S. Uterine Fibroid Treatment Market, By Procedure Type:
• Endometrial Ablation
• MRI Guided Procedures
• MRI-guided Percutaneous Laser Ablation
• MRI-guided Transcutaneous Focused Ultrasound
• Hysterectomy
• Abdominal Hysterectomy
• Vaginal Hysterectomy
• Laparoscopic Hysterectomy
• Robotic Hysterectomy
• Hysteroscopic Morcellation
• Myomectomy
• Open Myomectomy
• Laparoscopic Myomectomy
• Robotic Myomectomy
• Uterine Artery Embolization
• Radiofrequency Ablation
• Others
• U.S. Uterine Fibroid Treatment Market, By End User:
• Hospitals
• Ambulatory Surgical Centers
• Company Profiles
• Blue Endo
• Boston Scientific Corporation or its affiliates
• CooperSurgical, Inc.
• Karl Storz SE & Co. KG
• Myovant Sciences GmbH (Sumitovant Biopharma Ltd.)
• Halt Medical, Inc. (Acquired by Hologic, Inc.)
• LiNA Medical ApS
• Merit Medical Systems
• Olympus Corporation
• Richard Wolf GmbH